<?xml version="1.0" encoding="UTF-8"?>
<ref id="B38-vaccines-07-00072">
 <label>38.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cabral-Miranda</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Heath</surname>
    <given-names>M.D.</given-names>
   </name>
   <name>
    <surname>Mohsen</surname>
    <given-names>M.O.</given-names>
   </name>
   <name>
    <surname>Gomes</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Engeroff</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Flaxman</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Leoratti</surname>
    <given-names>F.M.S.</given-names>
   </name>
   <name>
    <surname>El-Turabi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Reyes-Sandoval</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Skinner</surname>
    <given-names>M.A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax</article-title>
  <source>Vaccines</source>
  <year>2017</year>
  <volume>5</volume>
  <elocation-id>10</elocation-id>
  <pub-id pub-id-type="doi">10.3390/vaccines5020010</pub-id>
  <?supplied-pmid 28468322?>
  <pub-id pub-id-type="pmid">28468322</pub-id>
 </element-citation>
</ref>
